Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Induction of Remission in RA Patients with Low Disease Activity
NCT00521924Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of infliximab in rheumatoid arthritis (RA) (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Patients in Remission According to Disease Activity Score (DAS) 28 (< 2.6) at 38 weeks. Started Jun 2007; status: terminated.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00521924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521924.